SCHEMBL1324347

SCHEMBL1324347

CCOC(=O)C1(N(NC(=O)OCc2ccccc2)C(=O)OCc2ccccc2)CC(=O)NC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 2/20 0.38
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LGMN Q99538 1/20 0.35
NAAA Q02083 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
ADAM17 P78536 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293955 0.88 DDB1 (0.44) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL13651747 0.79 DDB1 (0.39) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL27299225 0.77 DDB1 (0.43) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL498349 0.76 DDB1 (0.47) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL560681 0.76 DDB1 (0.47) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL2271664 0.75 AKT1 (0.36) CTSLCTSBCTSS
SCHEMBL12355229 0.70 DDB1 (0.47) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL28436910 0.70 SMN1; SMN2 (0.46) SMN1; SMN2LMNANPC1RAB9AGAA
SCHEMBL2297578 0.69 DDB1 (0.49) DDB1CRBNSMN1; SMN2LMNANPC1
SCHEMBL10611547 0.67 DDB1 (0.62) DDB1CRBNSMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US claimed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US claimed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US claimed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US claimed
US-8415487-B2 Process for preparing (3R)-2′-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-A]pyrazine]-1′,2,3′,5(2H′)-tetraone DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-04-09 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-20120010405-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND TANAKA DAISUKE (JP) 2012-01-12 US disclosed
US-8058456-B2 Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-11-15 US disclosed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US disclosed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US disclosed
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-04 US disclosed
US-20090286980-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-11-19 US disclosed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME SLC5A1, TERT, CBR3 DDB1 3636/4885CRBN 3259/4885SMN1; SMN2 3912/4885
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate REN, PKD1, KCNT1 DDB1 3570/4885CRBN 4418/4885SMN1; SMN2 2198/4885
US-20090286980-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND REN, GPR119, RANBP1 DDB1 4446/4885CRBN 4856/4885SMN1; SMN2 3700/4885
US-20120010405-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND REN, GPR119, RANBP1 DDB1 4446/4885CRBN 4856/4885SMN1; SMN2 3700/4885
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME CBR3, TERT, NOX4 DDB1 3985/4885CRBN 3626/4885SMN1; SMN2 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.